Endothelial catabolism of extracellular adenosine during hypoxia: The role of surface adenosine deaminase and CD26

Blood

Volumn 108, Issue 5, 2006, Pages 1602-1610

  Eltzschig, Holger K ^a   Faigle, Marion ^a   Knapp, Simone ^a   Karhausen, Jorn ^a   Ibla, Juan ^a   Rosenberger, Peter ^a   Odegard, Kirsten C ^a   Laussen, Peter C ^a   Thompson, Linda F ^a   Colgan, Sean P ^a  

^a Department of Anesthesiology and Intensive Care Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; DIPEPTIDYL PEPTIDASE IV; GLYCOPROTEIN GP 120; MESSENGER RNA; PENTOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CATABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 33748149076     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-001016     Document Type: Article

References (46)

1. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Ann Rev Immunol. 2004;22:657-682.
2. Ogawa S, Koga S, Kuwabara K, et al. Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels. Am J Physiol. 1992;262:C546-C554.
3. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood. 2004;104:3986-3992.
4. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull. 2004;70:71-86.
5. Thompson LF, Eltzschig HK, Ibla JC, et al. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during Hypoxia. J Exp Med. 2004;200:1395-1405.
6. Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;198:783-796.
7. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916-920.
8. Taylor CT, Colgan SP. Therapeutic targets for hypoxia-elicited pathways. Pharm Res. 1999;16:1498-1505.
9. Kempf VAJ, Lebiedziejewski M, Alitalo K, et al. Activation of hypoxia-inducible Factor-1 in bacillary angiomatosis: evidence for a role of hypoxia-inducible factor-1 in bacterial infections. Circulation. 2005;111:1054-1062.
10. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003;112:645-657.
11. Peyssonnaux C, Datta V, Cramer T, et al. HIF-1{alpha} expression regulates the bactericidal capacity of phagocytes. J Clin Invest. 2005;115:1806-1815.
12. Saito H, Nishimura M, Shinano H, et al. Plasma concentration of adenosine during normoxia and moderate hypoxia in humans. Am J Respir Crit Care Med. 1999;159:1014-1018.
13. Phillis JW, O'Regan MH, Perkins LM. Measurement of rat plasma adenosine levels during normoxia and hypoxia. Life Sci. 1992;51:PL149-PL152.
14. Eltzschig HK, Abdulla P, Hoffman E, et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med. 2005;202:1493-1505.
15. Blackburn MR. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol Sci. 2003;24:66-70.
16. Driver AG, Kukoly CA, Ali S, Mustafa SJ. Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis. 1993;148:91-97.
17. Huszar E, Vass G, Vizi E, et al. Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J. 2002;20:1393-1398.
18. Fozard JR, Hannon JP. Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. Pulm Pharmacol Ther. 1999;12:111-114.
19. Blackburn MR, Volmer JB, Thrasher JL, et al. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med. 2000;192:159-170.
20. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Blackburn MR. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol. 2005;175:1937-1946.
21. Sun C-X, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest. 2005;115:35-43.
22. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99:683-690.
23. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med. 1998;188:1433-1443.
24. Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110:993-1002.
25. Hashikawa T, Hooker SW, Maj JG, et al. Regulation of adenosine receptor engagement by ectoadenosine deaminase. FASEB J. 2004;18:131-133.
26. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993;261:466-469.
27. Dong RP, Kameoka J, Hegen M, et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol. 1996;156:1349-1355.
28. Strauss PR. Murine lymphocytes and lymphocyte cell lines secrete adenosine deaminase. Adv Exp Med Biol. 1986;195:275-282.
29. Schrader WP, West CA, Miczek AD, Norton EK. Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction. J Biol Chem. 1990;265:19312-19318.
30. Blanco J, Valenzuela A, Herrera C, Lluis C, Hovanessian AG, Franco R. The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression. FEBS Lett. 2000;477:123-128.
31. Valenzuela A, Blanco J, Callebaut C, et al. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J Immunol. 1997;158:3721-3729.
32. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209-294.
33. Law WR, Valli VE, Conlon BA. Therapeutic potential for transient inhibition of adenosine deaminase in systemic inflammatory response syndrome. Crit Care Med. 2003;31:1475-1481.
34. Cohen ES, Law WR, Easington CR, et al. Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis. Am J Respir Crit Care Med. 2002;166:16-20.
35. Adanin S, Yalovetskiy IV, Nardulli BA, Sam AD 2nd, Jonjev ZS, Law WR. Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis. Am J Physiol Regul Integr Comp Physiol. 2002;282:R1324-R1332.
36. Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 1998;18:768-776.
37. Yamamoto M, Nishimura M, Kobayashi S, Akiyama Y, Miyamoto K, Kawakami Y. Role of endogenous adenosine in hypoxic ventilatory response in humans: a study with dipyridamole. J Appl Physiol. 1994;76:196-203.
38. Lefkowitz RJ, Whalen EJ. β-arrestins: traffic cops of cell signaling. 2004;16:162-168.
39. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408:720-723.
40. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286:2495-2498.
41. Perry SJ, Baillie GS, Kohout TA, et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta -arrestins. Science. 2002;298:834-836.
42. Jin X, Shepherd RK, Duling BR, Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest. 1997;100:2849-2857.
43. Dinjens WN, ten Kate J, Wijnen JT, et al. Distribution of adenosine deaminase-complexing protein in murine tissues. J Biol Chem. 1989;264:19215-19220.
44. Saura CA, Mallol J, Canela EI, Lluis C, Franco R. Adenosine deaminase and A1 adenosine receptors internalize together following agonist-induced receptor desensitization. J Biol Chem. 1998;273:17610-17617.
45. Herrera C, Casado V, Ciruela F, et al. Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol Pharmacol. 2001;59:127-134.
46. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775-787.